Various types of induced pluripotent stem (iPS) cells have been established by different methods, and each type exhibits different biological properties. Before iPS cell-based clinical applications can be initiated, detailed evaluations of the cells, including their differentiation potentials and tumorigenic activities in different contexts, should be investigated to establish their safety and effectiveness for cell transplantation therapies. Here we show the directed neural differentiation of murine iPS cells and examine their therapeutic potential in a mouse spinal cord injury (SCI) model. "Safe" iPS-derived neurospheres, which had been pre-evaluated as nontumorigenic by their transplantation into nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse brain, produced electrophysiologically functional neurons, astrocytes, and oligodendrocytes in vitro. Furthermore, when the safe iPS-derived neurospheres were transplanted into the spinal cord 9 d after contusive injury, they differentiated into all three neural lineages without forming teratomas or other tumors. They also participated in remyelination and induced the axonal regrowth of host 5HT + serotonergic fibers, promoting locomotor function recovery. However, the transplantation of iPSderived neurospheres pre-evaluated as "unsafe" showed robust teratoma formation and sudden locomotor functional loss after functional recovery in the SCI model. These findings suggest that preevaluated safe iPS clone-derived neural stem/progenitor cells may be a promising cell source for transplantation therapy for SCI.
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neural stem/progenitor cell | cell transplantation | regenerative medicine | remyelination | axonal regrowth G iven their ability to generate all types of neural cells, neural stem/progenitor cells (NS/PCs) are a promising source for cell replacement therapy for various intractable CNS disorders (reviewed in refs. [1] [2] [3] [4] [5] [6] . Notably, ES cells have great developmental plasticity and can be induced to become NS/PCs with specific differentiation potentials (7-11), making them a major candidate for cell replacement therapies for CNS disorders (12) (13) (14) (15) (16) . The clinical use of ES cells is complicated, however, by ethical and immunological concerns, both of which might be overcome by using pluripotent stem cells derived directly from a patient's own somatic cells (17) .
We recently reported the establishment of induced pluripotent stem (iPS) cells from mouse fibroblasts by the retroviral introduction of four factors (Oct3/4, Sox2, Klf4, and c-Myc) with selection for Fbxo15 expression (18) and Nanog expression (19, 20) . Compared with Fbxo15-selected iPS cells, Nanog-selected iPS cells more closely resembled ES cells' gene-expression pattern and could contribute to germline-competent adult chimeras (19) (20) (21) . More recently, we and others (22, 23 ) generated iPS cells without using c-Myc retroviruses, albeit with lower efficiency. The successful establishment of these iPS cell lines, along with initial reports showing efficacy in the therapeutic use of iPS cells in rodent models of sickle cell anemia (24) and Parkinson disease (25) , led us to examine the use of iPS cells as a treatment for spinal cord injury (SCI).
A number of important issues need to be addressed before a clinical trial using iPS cells as a cell-therapy source for SCI is initiated. First, a detailed evaluation of iPS cells' potential to generate neural cells compared with ES cells is required. Second, iPS cells are likely to carry a higher risk of tumorigenicity than ES cells, due to the inappropriate reprogramming of these somatic cells, the activation of exogenous transcription factors, or other reasons (25) (26) (27) . Thus, it is essential to confirm the safety of grafted iPSderived NS/PCs. Finally, the effectiveness of iPS-derived NS/PC transplantation as a treatment for SCI must be evaluated.
In the previous study, we pre-evaluated iPS clones for safety by transplanting iPS-derived neurospheres into the NOD/SCID mouse brain (27) . Here, we show that the transplantation of neurospheres derived from safe iPS cell clones into the injured spinal cord promoted functional recovery without any tumor formation. In contrast, the transplantation of neurospheres derived from unsafe iPS cells, showing robust teratoma formation in the NOD/ SCID mouse brain, also resulted in initial functional recovery, but was later followed by teratoma formation and deterioration of locomotor function. These data suggest that the evaluation of in vitro differentiation and in vivo tumorigenicity are important for identifying safe iPS clones for cell therapy, and that the NS/PCs derived from iPS clones deemed safe by such pre-evaluation are a promising source for cell therapy for SCI.
clones, according to the teratoma-forming activity of the iPSderived neurospheres after transplantation into the NOD/SCID mouse brain.
Here, we first performed a detailed examination of the neural differentiation potential of a safe iPS clone, 38C2, which was established from mouse embryonic fibroblasts (MEFs) by the introduction of four factors, including c-Myc, and by the selection for Nanog expression (19, 28) , and compared them with mouse ES cells (EB3) (29, 30) . 38C2 iPS cells and EB3 ES cells were induced into embryoid bodies (EBs) in medium containing a low concentration of retinoic acid, then dissociated and cultured in suspension in serum-free medium with FGF-2 for 7 or 8 d to form primary neurospheres (PNS) (38C2 iPS/EB3 ES-PNS) (29) . These PNSs were dissociated and formed secondary neurospheres (38C2 iPS/ EB3 ES-SNS) under the same conditions (Fig. 1A) . To induce further differentiation, 38C2 iPS-SNSs were adherently cultured in the absence of FGF-2, resulting in the generation of Tuj1 + neurons (4.9 ± 0.8%), GFAP + astrocytes (11.3 ± 1.2%), and CNPase + oligodendrocytes (3.7 ± 0.9%), as well as Nestin + neural progenitor cells (25.9 ± 6.5%; Fig. 1 B and C) , suggesting that 38C2 iPS-SNS have similar differentiation potentials to EB3 ES-SNS. The 38C2 iPS-PNSs could also generate TH + catecholaminergic, 5HT + serotonergic, and GAD67 + GABAergic neurons (Fig. S1 ). RT-PCR analysis of the expression of cell-type-specific markers in the progeny of the 38C2 iPS cells showed drastic decrease of the expression of undifferentiated ES cell marker genes, such as Nanog, Eras, and Oct3/4, and the up-regulation of neural markers such as Sox1, βIII-tubulin, and GFAP during the neural differentiation of 38C2 iPS cells, similar to EB3 ES cells (Fig. 1D) .
Moreover, electrophysiological analysis using whole-cell patch clamping in both the 38C2 iPS-PNS-and EB ES-PNS-derived neurons after 21-28 d of adherent differentiation showed tetrodotoxin (TTX; 1 μM)-sensitive repetitive action potentials in the current-clamp mode [38C2 iPS-PNS (n = 11 of 16) and EB3 ES-PNS (n = 5 of 7)] (Fig. S2A ) and very rapid inward currents immediately followed by transient outward currents in voltage-clamp mode ( Fig. S2B 1 and 2 ). Steady outward currents, similar to those mediated by delayed-rectifier K + channels, were also observed ( Fig. S2 B1 and D) . These findings suggest that 38C2 iPS-PNSs produced neuronal cells equipped with functional channels that could generate and modify action potentials (SI Text).
Safe MEF-iPS Cells Can Differentiate into Trilineage Neural Cells in the
Injured Spinal Cord Without Tumorigenesis. Previously, we confirmed that SNSs from the safe 38C2 MEF-iPS cell clone survived and showed no teratoma-forming activity in the NOD/ SCID mouse brain for 24 wk after transplantation (27) (Fig. S3 ). 38C2 iPS-SNSs that were transplanted into the intact spinal cord survived and differentiated into trilineage neural cells without any tumorigenesis (Fig. S4) . Next, to evaluate their therapeutic effects in the mouse SCI model, we transplanted 38C2 iPS-SNSs into the contused spinal cord 9 d after injury and compared them with EB3 ES-SNSs, using adult fibroblasts and PBS as controls. We also made a comparison with 38C2 iPS-PNSs, because we recently confirmed that the transplantation of ES cell-derived SNSs, but not PNSs, provides therapeutic benefit after SCI (31) . We transplanted 38C2 iPS-SNSs that had been prelabeled by lentivirus to express both CBRluc and mRFP (32, 33) into the lesion epicenter 9 d after the injury. Bioluminescence imaging (BLI) analysis (34) , which detects luciferase photon signals only from living cells, revealed an approximate graft survival rate of 18% at 35 d after transplantation ( Fig. 2A) . We also histologically confirmed that the grafted cells survived and exhibited no apparent evidence of tumorigenesis (Fig. 2B) , and that there were no Nanog + cells (Fig. S5 ), at least during our observation period. Grafted RFP + cells were located mainly around the lesion epicenter, whereas some cells had migrated as far as 4 mm rostral and caudal to the graft site (Fig. 2C) . In the injured spinal cord, the grafted 38C2 iPS-SNSs differentiated into three types of neural cells, including Hu + neurons (31.4 ± 1.1%), GFAP + astrocytes (49.3 ± 4.5%), and π-GST + oligodendrocytes (14.4 ± 3.0%), whereas 38C2 iPS-PNSs differentiated dominantly into neurons-that is, Hu + neurons (50.4 ± 3.8%), GFAP + astrocytes (14.9 ± 0.6%), and π-GST + oligodendrocytes (4.6 ± 1.8%) (Fig. 2 D and E and Fig. S6 ).
Transplantation of SNSs Derived from Safe MEF-iPS Cells into the Injured Spinal Cord Promotes Functional Recovery. The contusive SCI initially caused complete paralysis, followed by gradual recovery that reached a plateau. There were statistically significant differences in Basso mouse scale (BMS) between the 38C2 iPS-SNS and PBS groups at 21, 28, 35, and 42 d after injury, whereas no significant difference was observed between the 38C2 iPS-SNS and EB3 ES-SNS groups. Forty-two days after injury, the 38C2 iPS-SNS-grafted animals could lift their trunks and had significantly better BMS than the PBS control or adult fibroblast-treated animals, which were unable to support their body weight with their hindlimbs (Fig. 3A) . To reveal the potential mechanism of functional recovery after 38C2 iPS-SNS transplantation, we conducted further histological analyses. By Luxol Fast Blue (LFB) staining, 38C2 iPS-SNS-grafted mice showed a significantly larger myelinated area at the lesion epicenter than the PBS control mice at 42 d after injury (Fig. 3B) . We also found that grafted 38C2 iPS-SNSderived cells myelinated NF200 + host neuronal fibers, confirmed by the positive staining of RFP and myelin basic protein (MBP; Fig.  3C ), indicating that graft cell-derived oligodendrocytes were capable of remyelination. For further confirmation of the myelinating ability of 38C2 iPS-SNSs, we transplanted 38C2 iPS-SNSs into the injured spinal cord of MBP-null shiverer mice, a severely hypoand dysmyelinating mutant mouse that lacks the major dense line of CNS myelin (35) . Myelinating potential of the grafted 38C2 iPS-SNS-derived cells was confirmed, exhibiting MBP + deposits (Fig.  3D ) and the major dense line, by electron microscopic analysis (Fig. 3E) .
To determine the effect of the grafted 38C2 iPS-SNSs on serotonergic nerve fibers, which are important for the motor functional recovery of hind limbs (36, 37), we immunostained for 5HT and quantified the positive area at the distal cord 1, 2, and 6 wk after injury. Some of the nerve fibers associated with graft cell-derived Hu + neurons were identified as 5HT + serotonergic fibers, and were prominent at the distal cord compared with the PBS control group (Fig. 4 A-C) . Quantitative analysis of the serotonergic innervation of the distal cord revealed a significant difference between the 38C2 iPS-SNS and PBS control groups (Fig. 4B) . The contusive injury (60 kDyn) resulted in a significant decrease in the number of 5HT + fibers at the distal cord, followed by a slight recovery, which is the nature of contusive SCI. The injection of PBS in the PBS control group did not induce any additional increase in the number of 5HT + fibers at the distal cord. In contrast, innervation of the distal cord by these 5HT + fibers was enhanced by the grafted 38C2 iPS-SNS 6 wk after SCI (Fig. 4B) . Moreover, 38C2 iPS-SNS-derived astrocytes, which exhibited a bipolar morphology with long processes, were observed closely associated with the 5HT + serotonergic fibers (Fig. 4D) .
Transplantation of Neurospheres Derived from Pre-Evaluated Safe or
Unsafe TTF-iPS Cells into the Injured Spinal Cord. Toward the goal of clinical application, we next examined the therapeutic potential of adult tissue-derived iPS cells. Among six TTF-iPS clones preevaluated in our previous study (27) , we used the safe 335D1 TTFiPS clone, which was generated with Nanog selection and without the transduction of c-Myc. We also used the unsafe 256H13 and 256H18 TTF-iPS clones (22, 27) , which were generated without genetic selection or the transduction of c-Myc, and were originally established from CAG-EGFP mice (22) . A subclone of RF8 ES cells carrying the Nanog-EGFP reporter (1A2) (19) was used as control. All of the TTF-iPS clones formed PNSs and SNSs (Fig.  5A) , and generated cells of all three neural lineages, similar to those derived from 1A2 ES cells (Fig. 5B) . We transplanted these TTF-iPS-derived SNSs into injured spinal cords 9 d after injury. Transplantation of the safe 335D1 iPS-SNS (prelabeled with RFP lentivirally) resulted in better functional recovery compared with the PBS control group, without any apparent tumorigenesis during our observation period (Fig. 5 C and D) . Grafted and survived RFP + 335D1 iPS-SNS-derived cells could differentiate into neural trilineages ( Fig. S7 A and B) . Furthermore, LFB staining revealed that 335D1 iPS-SNS-grafted mice had a significantly larger myelinated area at the lesion epicenter than the PBS control mice at 42 d after injury (Fig. S8 A and B) , and grafted RFP + 335D1 SNS-derived cells differentiated into MBP + oligodendrocytes (Fig. S8C) . However, all unsafe 256H18 iPS-SNS-grafted mice and one of 256H13 iPS-SNS-grafted mice formed teratomas containing EGFP + donor cells within the injured spinal cord (Fig. 5 E and F and Fig. S7C ). Histological analyses revealed that these teratomas contained epithelial and smooth muscle tissue (Fig. S9A) , and also exhibited Nanog immunoreactivity (Fig. 5G) . Although the motor functions gradually recovered in both groups to the same extent as in the safe 335D1 iPS-SNS recipients until 35 d after injury, the 256H18 iPS-SNSgrafted animals exhibited a sudden deterioration of motor function 42 d after injury. In contrast, the 256H13 iPS-SNS-grafted animals maintained their functional recovery at 42 d after injury (Fig. 5C) . Notably, in most mice of the 256H13 iPS-SNS group, scattered small clusters of Nanog + cells were observed in the spinal cords without obvious teratoma formation (Fig. S9 B and C) . Thus, we speculate that teratoma formation and subsequent deterioration of function recovery would occur in the 256H13 group if a longer observation period was set.
Discussion
In the present study, we showed that the pre-evaluated safe iPS cells could produce neurospheres containing NS/PCs (Fig. 1A) that give rise to trilineage neural cells, including several types of neurons ( Fig. 1 B and C) , and that the neurons were electrophysiologically functional in vitro similar to ES cells (Fig. S2) .
Based on these safety assessments and in vitro findings, we performed an in vivo study using the safe 38C2 MEF-iPS cell clone. Grafted 38C2 iPS-SNSs differentiated into neurons, astrocytes, and oligodendrocytes without forming teratomas or other tumors, and promoted functional recovery after SCI, whereas 38C2 iPS-PNSs did not show any therapeutic effects (Fig. 3A) . These findings were compatible with our recent data on mouse ES cell-derived neurosphere transplantation into an identical mouse SCI model (31) . Transplantation of ES-derived SNSs, which can differentiate into neural trilineages, promoted remyelination, axonal regrowth and tissue sparing, leading to improved function. In contrast, predominantly neurogenic PNSs showed no therapeutic effects on SCI (31) . Thus, we elected to use iPS-SNSs and not iPS-PNSs for this study. In fact, the grafted 38C2 iPS-SNSs formed MBP + myelin sheaths within the injured spinal cord. We also confirmed the myelination potential of 38C2 iPS-SNS-derived cells in the spinal cord of the MBP-null shiverer mouse by electron microscopy (Fig. 3 D and E). These findings suggested the possibility of the remyelination of demyelinated axons by the grafted 38C2 iPS-SNS-derived oligodendrocytes, which may have contributed to the functional recovery of the grafted animals.
Another potential mechanism for functional recovery is axonal regrowth supported by iPS-SNS-derived astrocytes. Here, we observed grafted 38C2 iPS-SNS-derived GFAP + astrocytes, which exhibited a bipolar morphology with long processes extending along the axis of the spinal cord, caudal to the lesion epicenter, in close association with 5HT + host serotonergic fibers (Fig. 4D) . A previous report indicated that immature astrocytes derived from cells grafted into the injured spinal cord promote the outgrowth of 5HT + fibers by offering a growthpermissive surface (38) . Consistent with this finding, the transplantation of 38C2 iPS-SNSs promoted serotonergic innervation of the distal cord compared with the PBS control animals, thereby enhancing functional recovery after SCI (Fig. 4 A and B ) (36) . Furthermore, trophic factors, such as neurotrophin-3 (NT-3) and brain-derived neurotrophic factor (BDNF), were expressed in 38C2 iPS-SNSs, which could act as an integral part of the observed functional recovery (39, 40) . The tissue sparing (e.g., neuroprotection, axon sprouting and remyelination) and other effects, including functional remodeling of spinal locomotor circuits (41), of trophic factors secreted from grafted cells are considered to be important for functional recovery (42) . Thus, the combined effects of the 38C2 iPS-SNS-derived glial cells probably contributed to locomotor function recovery.
For clinical applications, the findings with TTF-iPS cells were promising, as most SCI patients are adults. The transplantation of SNSs derived from a pre-evaluated safe TTF-iPS clone promoted functional recovery after SCI without teratoma formation, like the SNSs from safe MEF-iPS clone did (Fig. 5D) . However, the transplantation of SNSs derived from the unsafe TTF-iPS cells resulted in teratoma formation and functional deterioration. The teratoma-forming activity of TTF-iPS-SNSs could be caused by the presence of undifferentiated cells that might be resistant to differentiation signals within the SNSs (27) . In fact, we recently reported that persistent presence of undifferentiated cells within iPS-SNSs highly correlated with teratoma-forming propensity, assayed by flow cytometric analysis using Nanog-EGFP reporter and transplantation into the brains of immunodeficient (NOD/ SCID) (27) . Before iPS cells of adult origin can be used clinically, important hurdles must still be overcome. Though new methods for establishing iPS cells are constantly being developed, including virus-free (43) and transgene-free (44) systems, a new strategy is needed to exclude undifferentiated cells from the differentiated progeny of iPS cells. These findings show that the pre-evaluation of iPS cells' in vitro differentiation potential could play a critical role in terms of their safety and therapeutic effects on the mouse SCI model. Thus, iPS-derived neurosphere transplantation has potential therapeutic use in SCI, when the iPS cell clones are carefully pre-evaluated.
From a clinical viewpoint, it is particularly encouraging that delaying the iPS-derived NS/PC transplantation (to 9 d after injury) enhanced both the survival of the grafted cells and functional recovery, the therapeutic effects of which is almost comparable to those of fetal CNS-derived NS/PCs transplantation (refs. 34 and 45) . This finding may also be applicable to the treatment of patients with SCI. Since our first report of iPS cells (18) , there has been increasing interest in their characteristics and therapeutic potential. Our present study demonstrates the therapeutic potential of iPS-derived NS/PCs for SCI repair. Before any clinical trial of human CNS disorders using iPS cells, it will be essential to preevaluate each iPS cell clone carefully to guarantee a safety level equal to other types of cells, such as Schwann cells (46, 47) and fetal-derived neurosphere cells (NS/PCs) (3), and to conduct preclinical transplantation studies using appropriate primate models (48, 49) .
Methods
Reverse-Transcription and RT-PCR. RNA was isolated with TRIzol (Invitrogen) according to the manufacturer's instructions. Total RNA (0.5 μg) was treated with TURBO DNase (Ambion) and then reverse-transcribed with oligo (dT) primer and SuperScript III (Invitrogen). The primers and PCR conditions used in this study are listed Table S1 .
Cell Culture, Neural Induction, and Immunocytochemistry. Mouse ES and iPS cells were cultured as described previously (19, 28, 29) . Mouse ES and iPS cells were differentiated into neurospheres via EBs treated with 10 −8 M retinoic acid (Sigma), as described previously with minor modification (28, 29) . (Detailed differentiation protocol is described in SI Text.) ES and iPS cell-derived neurospheres were dissociated and differentiated on poly-L-ornithine/fibronectincoated coverslips for 5 d and subjected to immunocytochemical analysis. The number of cells immunoreactive for each marker was counted and shown as the percentage of the total number of cells counterstained with Hoechst 33258. The antibodies used in this study are listed in Table S2 .
Lentivirus Production and Infection of Secondary Neurospheres. For BLI tracing of grafted 38C2 iPS-SNSs, we generated a modified lentivirus vector encoding both the click beetle red luciferase (CBRluc; Promega) and mRFP, pCSII-EFCBRluc-IRES2-mRFP (32, 33) . For lentivirus preparation, HEK-293T cells were transfected with pCSII-EF-CBRluc-IRES2-mRFP, pCAG-HIVgp, and pCMV-VSV-G-RSV-Rev, and the conditioned medium containing virus particles was concentrated and used for viral transduction.
Spinal Cord Injury Model and Transplantation. Adult female C57BL/6J mice (20-22 g) were anesthetized via an i.p. injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). A contusive spinal cord injury using an Infinite Horizon Impactor (60 kdyn; Precision Systems) was induced at the Th10 level as reported previously (34) . For transplantation, 5 × 10 5 cells of mouse ES/iPS cell-derived neurospheres, adult dermal fibroblasts in 2 μL of cell suspension, or PBS was injected into the lesion epicenter. Hindlimb motor function was evaluated by the locomotor rating of the Basso mouse scale (BMS) (50) for 42 d after injury. For the in vivo imaging of intact and injured spinal cords after the transplantation, a Xenogen-IVIS 100 cooled CCD optical macroscopic imaging system (SC BioScience) was used for BLI, as reported previously (34) (SI Text). All procedures were approved by the ethics committee of Keio University, and were in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health). Grafted animals were deeply anesthetized and intracardially perfused with 4% paraformaldehyde (PFA; pH 7.4). The dissected spinal cords were sectioned into 20-μm axial/sagittal sections using a cryostat and processed for histological analyses. Detailed conditions for histological analyses are described in SI Text.
Statistical Analysis. All data are reported as the mean ± SEM. An unpaired twotailed Student's t test was used for the analyses of in vitro and in vivo 38C2 iPS-SNS and ES-SNS differentiation efficiency (Figs. 1C and 2E ), 5HT + areas (Fig. 4B) , and LFB + areas (Fig. 2B) . Repeated-measures two-way ANOVA, followed by the Tukey-Kramer test, was used for BMS analysis. *P < 0.05, **P < 0.01.
